Stapuldencel-T

Drug Profile

Stapuldencel-T

Alternative Names: DCVAC PCa; DCVAC/PCa; Dendritic cell vaccine/Prostate cancer - Sotio

Latest Information Update: 08 Jun 2017

Price : $50

At a glance

  • Originator SOTIO
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 22 May 2017 Sotio completes a phase-II trial in Prostate cancer (Adjuvant therapy after primary radical prostatectomy, Early-stage disease) in Czech Republic (SC) (NCT02107404)
  • 20 Apr 2017 Sotio completes a phase II trial in Prostate cancer (Metastatic disease, First-line therapy, Combination therapy) in Czech Republic (SC) (SP001; EudraCT 2011-004735-32)
  • 20 Mar 2017 Sotio completes a phase II extension trial for Prostate cancer in Czech Republic (NCT02137746)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top